Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 213.00 |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 2,102.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 180.00 |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1,592.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -291.00 |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -2,476.00 |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1,604.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.10 Bn | 214.41 Mn | 7,118.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,118.00 |
| Mar 31, 2026 | 2,942.00 |
| Dec 31, 2025 | 4.14 Mn |
| Sep 30, 2025 | 6,876.00 |
| Jun 30, 2025 | 6,736.00 |
| Mar 31, 2025 | 13,775.00 |
| Dec 31, 2024 | 6,756.00 |
| Sep 30, 2024 | 6,433.00 |
| Jun 30, 2024 | 5,145.00 |
| Mar 31, 2024 | 26,251.00 |
| Dec 31, 2023 | 105,508.00 |
| Sep 30, 2023 | 60,567.00 |
| Jun 30, 2023 | 106,029.00 |
| Mar 31, 2023 | 41,580.00 |
| Dec 31, 2022 | -414.00 |
| Sep 30, 2022 | 151,867.00 |
| Jun 30, 2022 | 165,534.00 |
| Mar 31, 2022 | 30,353.00 |
| Dec 31, 2021 | 81,152.00 |
| Sep 30, 2021 | 235,450.00 |